Asciminib Shows Sustained Efficacy in Heavily Pretreated CML Patients with 39% Achieving Major Molecular Response
核心洞察
The ASC4OPT phase 3b study demonstrated that asciminib achieved a 39.4% major molecular response (MMR) rate at Week 48 in chronic myeloid leukemia (搜索) patients previously treated with two or more tyrosine kinase inhibitors.
Both dosing regimens (40 mg twice daily and 80 mg once daily) showed similar efficacy and safety profiles, with MMR rates increasing to approximately 44% by Week 96.
The safety profile remained favorable with 94% of patients experiencing any-grade adverse events, while only 7.1% discontinued treatment due to adverse events during the median 115-week exposure period.
The ASC4OPT study has demonstrated that asciminib, a first-in-class STAMP inhibitor, provides sustained clinical benefit in heavily pretreated chronic myeloid leukemia (搜索) (CML (搜索)) patients, with 39.4% achieving major molecular response (MMR) at Week 48. The international, multicenter, open-label phase 3b trial enrolled 169 patients with chronic phase CML who had previously received two or more tyrosine kinase inhibitors (TKIs).
Primary Efficacy Results
The study met its primary endpoint with an overall MMR rate of 39.4% (95% CI: 31.9, 47.3) at Week 48. Patients randomized to asciminib 40 mg twice daily achieved a 43.4% MMR rate (95% CI: 32.5, 54.7), while those receiving 80 mg once daily achieved 35.4% (95% CI: 25.1, 46.7). These response rates were numerically higher than those observed in the pivotal ASCEMBL study, where asciminib 40 mg twice daily achieved a 29.0% MMR rate at Week 48.
Response rates continued to improve over time, with MMR rates reaching similar levels in both arms at Week 96: 45.8% for the twice-daily regimen and 41.5% for the once-daily regimen. The estimated median time to first MMR was 22.7 weeks overall, with 13.1 weeks for the 40 mg twice-daily group and 23.9 weeks for the 80 mg once-daily group.
Deep Molecular Responses and Clinical Outcomes
Beyond MMR, patients achieved meaningful deep molecular responses. At Week 48, MR4 and MR4.5 rates were 17.0% and 10.3%, respectively, with the twice-daily regimen showing slightly higher rates (20.5% and 12.0%) compared to once-daily dosing (13.4% and 8.5%). These deep response rates remained stable through Week 96.
Nearly two-thirds of patients (63.6%) achieved BCR::ABL1IS ≤ 1% at Week 48, a clinically significant milestone associated with improved long-term outcomes and reduced risk of disease progression. This proportion increased to 64.8% by Week 96, demonstrating sustained benefit with continued treatment.
Dose Escalation Strategy
For patients not achieving MMR at Week 48 or losing response between Week 48 and Week 108, dose escalation to 200 mg once daily was permitted. Among the 40 patients who received this higher dose, 17.5% achieved MMR at Week 96, providing a therapeutic option for patients with suboptimal initial responses.
Safety and Tolerability Profile
The safety profile of asciminib remained consistent with previous studies, with 94.0% of patients experiencing any-grade adverse events and 37.5% experiencing Grade ≥3 events. Treatment discontinuation due to adverse events occurred in only 12 patients (7.1%), with thrombocytopenia (搜索) being the most common reason for discontinuation.
Pancreatic enzyme elevations, a known adverse event of interest, were observed in 22 patients (13.1%) overall, with most cases being asymptomatic laboratory findings. Only two Grade 3 increased lipase events and one Grade 3 hyperlipasemia event were reported, and no cases of pancreatitis (搜索) occurred.
Eleven arterial occlusive events were reported across both dosing arms, with four being Grade ≥3. One on-treatment death occurred due to cerebrovascular accident in a patient with multiple cardiovascular risk factors, which investigators assessed as not related to study drug.
Patient Population and Mutation Analysis
The study enrolled heavily pretreated patients, with most having discontinued their previous TKI due to resistance rather than intolerance. At baseline, 25 patients (14.8%) harbored BCR::ABL1 (搜索) mutations, with Y253H being the most common (n=6), followed by M244V and T315I (n=4 each).
Mutation analysis revealed important insights into resistance patterns. All six patients with Y253H mutations remained on treatment at data cutoff, with four achieving MMR at Week 48. In contrast, nearly all patients with M244V mutations discontinued treatment, suggesting this mutation confers significant resistance to asciminib.
Patient-Reported Outcomes
Quality of life assessments using the MDASI-CML (搜索) questionnaire showed sustained improvement, with symptom and interference scores decreasing from baseline and remaining stable through Week 96. Completion rates for the questionnaire remained high (90.9% to 94.7%), indicating good patient engagement and suggesting that asciminib treatment did not negatively impact daily activities.
Exploratory Cohort Results
An additional 30 patients already in MMR at baseline were enrolled in an exploratory cohort to assess asciminib's role in TKI-intolerant patients. The MMR maintenance rate at Week 48 was 93.3% overall, with 100% maintenance in the twice-daily arm and 87.5% in the once-daily arm. This high maintenance rate demonstrates asciminib's utility in patients who cannot tolerate other TKIs while maintaining molecular responses.
Clinical Implications
The ASC4OPT results support asciminib as an effective treatment option for patients with suboptimal response to ATP-competitive TKIs. The study's inclusion of patients in both failure and warning categories according to European LeukemiaNet 2020 criteria suggests that earlier switching to asciminib may improve response rates compared to waiting until treatment failure occurs.
Dr. Jorge Cortes, Chief of Hematology at UAB O'Neal Cancer Center, noted the importance of treatments that combine robust efficacy with favorable tolerability for CML (搜索) patients who require long-term therapy. The sustained response rates and manageable safety profile observed in ASC4OPT support asciminib's role in the evolving treatment landscape for CML patients with prior TKI exposure.